BDSI - BioDelivery Sciences International, Inc.
6.15 0.00 (0.00%)
After hours: 5:25PM EST
| Previous Close | 6.09 |
| Open | 6.11 |
| Bid | 6.14 x 3100 |
| Ask | 6.30 x 1400 |
| Day's Range | 6.03 - 6.30 |
| 52 Week Range | 2.80 - 6.45 |
| Volume | 2,309,117 |
| Avg. Volume | 915,496 |
| Market Cap | 553.058M |
| Beta (3Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.27 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.17 |
- Zacks
Protalix Finalizes Accelerated Approval Pathway for PRX-102
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
- Zacks
BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View
BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.
- Thomson Reuters StreetEvents
Edited Transcript of BDSI earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 BioDelivery Sciences International Inc Earnings Call
- Zacks
IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
- Zacks
5 Breakout Stocks for Explosive Returns
Picking breakout stocks is one of the most-favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
- Zacks
BioDelivery Sciences International (BDSI) Beats Q3 Earnings and Revenue Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 5.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations
BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million Raises Full Year 2019 Total Company Net Sales Expectations to $105 - $110 Million.
- GlobeNewswire
BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London
RALEIGH, N.C., Nov. 07, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- Simply Wall St.
Introducing BioDelivery Sciences International (NASDAQ:BDSI), The Stock That Zoomed 197% In The Last Three Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Zacks
BioDelivery Sciences International (BDSI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus
The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus
- Zacks
Zacks.com featured highlights include: Universal Forest Products, BioDelivery Sciences International, CBIZ, Euronav and The Bancorp
Zacks.com featured highlights include: Universal Forest Products, BioDelivery Sciences International, CBIZ, Euronav and The Bancorp
- Insider Monkey
Were Hedge Funds Right About Selling BioDelivery Sciences International, Inc. (BDSI)?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
- Zacks
5 Stocks With Recent Price Strength to Enhance Your Return
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
- Zacks
5 Top Momentum Stocks in October That Still Have Upside Left
Possibility of at least an interim trade deal between the largest trading countries of the world boosted investors' confidence on risky assets like equities.
- Zacks
Here's Why Momentum Investors Will Love BioDelivery Sciences International (BDSI)
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
- GlobeNewswire
BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019
RALEIGH, N.C., Oct. 30, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic.
- Zacks
Moving Average Crossover Alert: BioDelivery Sciences International
BioDelivery Sciences International, Inc. (BDSI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Will BioDelivery Sciences Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor BioDelivery Sciences.
- American City Business Journals
From Iqvia to Cree: Execs with ties to Triangle companies inked millions in Q3 stock sales
Once again, top executives with ties to Triangle companies are walking away with millions of dollars in insider stock sales.
- GlobeNewswire
BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred.
- GlobeNewswire
BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
RALEIGH, N.C., Sept. 17, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- Zacks
BioDelivery (BDSI) Up 8.9% Since Last Earnings Report: Can It Continue?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
RALEIGH, N.C., Aug. 29, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
